Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) released its financial results for the first quarter of 2026, revealing a significant decline in revenue and a net loss, as the company navigates a shift in a major client project and continues its strategic transformation. For the three months ended March 31, 2026, revenue was $648,140, a 44% decrease from the same period in the prior year. The decline was driven almost entirely by a change of activities in a large project for a major customer, which had been expected to continue through 2026.
Gross profit for the quarter was $202,231, with a gross margin of 31.2%, compared to 53.6% in Q1 2025. Margins were negatively impacted by underutilized capacity, as the company maintained staffing and operational readiness in anticipation of executing the planned customer work. The net and comprehensive loss was $401,295, compared to net income of $63,523 in the prior year. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, the relocation of the former Keystone Labs operations to a new facility, and investments in a stronger sales organization.
Despite the quarterly results, Innovotech is advancing its strategic transformation, including strengthening its leadership and commercial teams, and completing its OTCQB listing in the United States. The company maintains a strong liquidity position and a meaningful equity base, providing flexibility to manage near-term volatility while continuing to execute its longer-term strategy. CEO Craig Milne stated, "Management remains committed to investing in a more diversified, resilient, and scalable platform. The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk."
The company's unaudited consolidated financial statements and Management's Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. Innovotech is a life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. It is a recognized leader in biofilm science and antimicrobial testing, operating through ISO-certified and GMP-accredited laboratories. More information is available at https://www.innovotech.ca.
This document may contain forward-looking statements subject to risks and uncertainties, including regulatory outcomes, reliance on a small number of customers, fluctuations in operating results, and intellectual property matters. The company undertakes no obligation to update forward-looking statements except as required by law.
